Nucleic Acid Therapeutics

Aims & Scope

Nucleic Acid Therapeutics is the leading journal in its field focusing on cutting-edge basic research, therapeutic applications, and drug development using nucleic acids or related compounds to alter gene expression.

The Journal examines many new approaches for using nucleic acids as therapeutic agents or in modifying nucleic acids for therapeutic purposes including: oligonucleotides, gene modification, aptamers, RNA nanoparticles, and ribozymes.

View Aims & Scope

---

Metrics & Ranking

Impact Factor

Year	Value
2025	4.7
2024	4.00

SJR (SCImago Journal Rank)

Year	Value
2024	1.499

Quartile

Year	Value
2024	Q1

h-index

Year	Value
2024	81

Journal Rank

Year	Value
2024	2390

Journal Citation Indicator

Year	Value
2024	514

---

---

Abstracting & Indexing

Journal is indexed in leading academic databases, ensuring global visibility and accessibility of our peer-reviewed research.

• Scopus
• Google Scholar
• Web of Science
• Medline
• Embase

---

Subjects & Keywords

Journal’s research areas, covering key disciplines and specialized sub-topics in Biochemistry, Genetics and Molecular Biology and Pharmacology, Toxicology and Pharmaceutics, designed to support cutting-edge academic discovery.

---

Most Cited Articles

The Most Cited Articles section features the journal's most impactful research, based on citation counts. These articles have been referenced frequently by other researchers, indicating their significant contribution to their respective fields.

• Phosphorothioates, Essential Components of Therapeutic Oligonucleotides

  Citation: 580

  Authors: Fritz

• GalNAc-siRNA Conjugates: Leading the Way for Delivery of RNAi Therapeutics

  Citation: 560

  Authors: Aaron D., Steven F.

• Lipid Nanoparticles Enabling Gene Therapies: From Concepts to Clinical Utility

  Citation: 457

  Authors: Jayesh A., Pieter R., Roy

• Molecular Mechanisms of Antisense Oligonucleotides

  Citation: 324

  Authors: Stanley T.

• FDA Approves Eteplirsen for Duchenne Muscular Dystrophy: The Next Chapter in the Eteplirsen Saga

  Citation: 308

  Authors: Annemieke, Arthur M.

• RNA Sequencing: Platform Selection, Experimental Design, and Data Interpretation

  Citation: 185

  Authors: Yongjun, David R.

• Polymers in Small-Interfering RNA Delivery

  Citation: 174

  Authors: Kaushik, Ran, Won Jong

• CpG Still Rocks! Update on an Accidental Drug

  Citation: 168

  Authors: Arthur M.

• FDA Approval of Nusinersen for Spinal Muscular Atrophy Makes 2016 the Year of Splice Modulating Oligonucleotides

  Citation: 167

  Authors: Annemieke

• Long Non-Coding RNAs: Challenges for Diagnosis and Therapies

  Citation: 153

  Authors: Yolanda, Maite

---